Jaguar Health Reports Successful Stockholder Meeting and Progress on Clinical Trial

Jaguar Health, Inc., a commercial stage pharmaceuticals company, informed on April 9, 2024, the positive outcomes of its Special Meeting of Stockholders. During this assembly, all four proposals presented were approved. These proposals were elaborately described in a definitive proxy statement available to the public via the Securities and Exchange Commission's website and the company's corporate platform.

The company also shared it is not considering a reverse split of its voting common stock at the moment despite receiving an extended grace period through August 13, 2024, from The Nasdaq Stock Market to meet the $1.00 bid price requirement. This decision underscores the commitment to safeguarding its Nasdaq listing without immediate structural changes.

In addition, Jaguar highlighted its Phase 3 OnTarget trial of crofelemer for preventing cancer therapy-related diarrhea as a critical focus. The trial's top line results are eagerly awaited, marking a significant step in the company's clinical advancements.